HONG KONG SAR - Media OutReach Newswire - 8 November 2024 - AIM Vaccine (06660.HK), the world's second largest supplier of rabies vaccines, announced on 7^th November that the application for clinical trial of the iterative-process highly-effective human diploid rabies vaccine developed by the Company has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.